It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Centriolar satellites are multiprotein aggregates that orbit the centrosome and govern centrosome homeostasis and primary cilia formation. In contrast to the scaffold PCM1, which nucleates centriolar satellites and has been linked to microtubule dynamics, autophagy, and intracellular trafficking, the functions of its interactant CEP131 beyond ciliogenesis remain unclear. Using a knockout strategy in a non-ciliary T-cell line, we report that, although dispensable for centriolar satellite assembly, CEP131 participates in optimal tubulin glycylation and polyglutamylation, and microtubule regrowth. Our unsupervised label-free proteomic analysis by quantitative mass spectrometry further uncovered mitochondrial and apoptotic signatures. CEP131-deficient cells showed an elongated mitochondrial network. Upon cell death inducers targeting mitochondria, knockout cells displayed delayed cytochrome c release from mitochondria, subsequent caspase activation, and apoptosis. This mitochondrial permeabilization defect was intrinsic, and replicable in vitro with isolated organelles. These findings extend CEP131 functions to life-and-death decisions and propose ways to interfere with mitochondrial apoptosis.
A combination of quantitative proteomics and functional analyses in a T-cell line unveils a role for the centriolar satellite component CEP131 in the maintenance of proteostasis and the fine-tuning of mitochondrial apoptosis.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 Team SOAP, CRCI2NA, Nantes University, INSERM, CNRS, Université d’Angers, Nantes, France (GRID:grid.4817.a) (ISNI:0000 0001 2189 0784); Equipe Labellisée Ligue Contre le Cancer, Nantes, France (GRID:grid.4817.a)
2 Team PETRY, CRCI2NA, Nantes University, INSERM, CNRS, Université d’Angers, Nantes, France (GRID:grid.4817.a) (ISNI:0000 0001 2189 0784)
3 Team SOAP, CRCI2NA, Nantes University, INSERM, CNRS, Université d’Angers, Nantes, France (GRID:grid.4817.a) (ISNI:0000 0001 2189 0784); Equipe Labellisée Ligue Contre le Cancer, Nantes, France (GRID:grid.4817.a); Institut de Cancérologie de l’Ouest (ICO), Saint-Herblain, France (GRID:grid.418191.4) (ISNI:0000 0000 9437 3027)